Downregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposis

Respiratory Research

Volumn 6, Issue , 2005, Pages

  Cardell, Lars Olaf ^a   Hägge, Magnus ^a   Uddman, Rolf ^a   Adner, Mikael ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; FLUTICASONE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROID;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; MALE; NASAL BIOPSY; NOSE POLYP; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; AGED; COMPLICATION; CONTROLLED CLINICAL TRIAL; HAY FEVER; METABOLISM; MIDDLE AGED; NASAL POLYPS; NOSE MUCOSA; PATHOLOGY;

ADULT; AGED; DOWN-REGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL POLYPS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RHINITIS, ALLERGIC, SEASONAL;

EID: 27844595888     PISSN: 1465993X     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-6-132     Document Type: Article

References (39)

1. Wang D, Clement P, Smitz J, De Waele M, Derde MP: Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995, 106(3):278-285.
2. Bachert C, Hauser U, Prem B, Rudack C, Ganzer U: Proinflammatory cytokines in allergic rhinitis. Eur Arch Otorhinolaryngol 1995, 252 Suppl 1:S44-49.
3. Baraniuk JN: Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997, 99(2):S763-772.
4. Kinhult J, Egesten A, Benson M, Uddman R, Cardell LO: Increased expression of surface activation markers on neutrophils following migration into the nasal lumen. Clin Exp Allergy 2003, 33(8):1141-1146.
5. Pawankar R: Nasal polyposis: an update: editorial review. Curr Opin Allergy Clin Immuno1 2003, 3(1):1-6.
6. Benson M, Adner M, Cardell LO: Cytokines and cytokine receptors in allergic rhinitis: how do they relate to the Th2 hypothesis in allergy? Clin Exp Allergy 2001, 31(3):361-367.
7. Bernstein JM, Ballow M, Rich G, Allen C, Swanson M, Dmochowski J: Lymphocyte subpopulations and cytokines in nasal polyps: is there a local immune system in the nasal polyp? Otalaryngol Head Neck Surg 2004, 130(5):526-535.
8. Dinarello CA: Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 1997, 11(3):91-103.
9. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101(11):1311-1318.
10. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, Chi Y, Kurtz TW: Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000, 136(5):609-616.
11. Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg RS: Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002, 8(5):330-339.
12. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347(6294):645-650.
13. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994, 91(15):7355-7359.
14. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137(1):354-366.
15. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W: The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996, 384(6604):39-43.
16. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T: Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 2001, 276(49):46260-46267.
17. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83(5):803-812.
18. Duval C, Fruchart JC, Staels B: PPAR alpha, fibrates, lipid metabolism and inflammation. Arch Mal Coeur Vaiss 2004, 97(6):665-672.
19. Hsueh WA, Bruemmer D: Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004, 43(2):297-305.
20. Michalik L, Desvergne B, Wahli W: Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004, 4(1):61-70.
21. Daynes RA, Jones DC: Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002, 2(10):748-759.
22. Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, Capron M, Dombrowicz D: Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 2003, 198(3):411-421.
23. Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P: PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol 2003, 139(1):163-171.
24. Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret MC, Mechighel P, Megret J, Leseche G, Aubier M, Pretolani M: Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1487-1494.
25. Wang AC, Dai X, Luu B, Conrad DJ: Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 2001, 24(6):688-693.
26. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391(6662):79-82.
27. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391(6662):82-86.
28. Honda K, Marquillies P, Capron M, Dombrowicz D: Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 2004, 113(5):882-888.
29. Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA: Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol 2003, 170(5):2663-2669.
30. Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169(3):453-459.
31. Harris SG, Phipps RP: The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 2001, 31(4):1098-1105.
32. Faveeuw C, Fougeray S, Angeli V, Fontaine J, Chinetti G, Gosset P, Delerive P, Maliszewski C, Capron M, Staels B et al. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 2000, 486(3):261-266.
33. Sugiyama H, Nonaka T, Kishimoto T, Komoriya K, Tsuji K, Nakahata T: Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. Eur J Immunol 2000, 30(12):3363-3370.
34. Sugiyama H, Nonaka T, Kishimoto T, Komoriya K, Tsuji K, Nakahata T: Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells. FEBS Lett 2000, 467(2-3):259-262.
35. Thieringer R, Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L, Moller DE, Wright SD, Berger J: Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 2000, 164(2):1046-1054.
36. Kuenzli S, Saurat JH: Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol 2003, 149(2):229-236.
37. Wiesenberg I, Chiesi M, Missbach M, Spanka C, Pignat W, Carlberg C: Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608. Mol Pharmacol 1998, 53(6):1131-1138.
38. Spiegelman BM: PPARgamma in monocytes: less pain, any gain? Cell 1998, 93(2):153-155.
39. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM: PPARgamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001, 7(1):48-52.